How long has keppra been on the market?

When did Keppra first hit shelves?
Keppra (levetiracetam) received FDA approval in March 1999, the same month it went on sale in the United States. [1]

How long has it actually been on the market?
From its first approval in 1999 to 2024 it has been available for 25 years. That span covers its initial launch, subsequent indications for partial‑onset seizures, status epilepticus, and adjunctive therapy in children. [1]

What about its patents—do they still protect the brand?
The original U.S. patents covering levetiracetam’s composition and use expired in 2018, after which generic manufacturers entered the market. Some secondary patents on drug delivery or formulation persisted into the early 2020s but the core product is now generic‑eligible. [2]

How many generic versions are on the market today?
At least eight generic manufacturers have approved levetiracetam products in the U.S., with most selling in the low‑$5–$10 weekly cost range, far below the original brand price. [3]

Has the price of Keppra changed over time?
When it launched, Keppra sold for about $1,000–$1,500 per month. After generics entered, the average wholesale cost dropped to around $200–$300 per month, a 70‑80% reduction. Insurance coverage and pharmacy benefit manager negotiations continue to drive further discounts. [3]

Which drugs are filling the same niche now?
Other antiepileptics such as brivaracetam, cenobamate, and lacosamide are marketed for partial‑onset seizures, but levetiracetam remains the most widely prescribed due to its proven efficacy, ease of dosing, and low drug–drug interaction profile. [1]

Why has Keppra stayed popular for so long?
Keppra’s predictable pharmacokinetics, once‑daily dosing, and tolerable side‑effect profile make it a first‑line option in many epilepsy management guidelines. Its broad approval for both adults and children also keeps it in routine clinical use. [1]